# Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

> **NCT03936270** · PHASE2 · COMPLETED · sponsor: **Latin American Cooperative Oncology Group** · enrollment: 43 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Palbociclib 125mg
- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT03936270
- **Lead sponsor:** Latin American Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-05
- **Primary completion:** 2022-01-18
- **Final completion:** 2023-05-02
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03936270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03936270, "Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT03936270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*